433 related articles for article (PubMed ID: 33827074)
1. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
Choksi TT; Zhang H; Chen T; Malhotra N
Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
[TBL] [Abstract][Full Text] [Related]
2. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
3. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort.
Lu Y; Van Zandt M; Liu Y; Li J; Wang X; Chen Y; Chen Z; Cho J; Dorajoo SR; Feng M; Hsu MH; Hsu JC; Iqbal U; Jonnagaddala J; Li YC; Liaw ST; Lim HS; Ngiam KY; Nguyen PA; Park RW; Pratt N; Reich C; Rhee SY; Sathappan SMK; Shin SJ; Tan HX; You SC; Zhang X; Krumholz HM; Suchard MA; Xu H
JAMA Netw Open; 2022 Mar; 5(3):e223877. PubMed ID: 35323951
[TBL] [Abstract][Full Text] [Related]
5. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
7. First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care.
Sinnott SJ; Douglas IJ; Smeeth L; Williamson E; Tomlinson LA
BMJ; 2020 Nov; 371():m4080. PubMed ID: 33208355
[TBL] [Abstract][Full Text] [Related]
8. Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19.
Chouchana L; Beeker N; Garcelon N; Rance B; Paris N; Salamanca E; Polard E; Burgun A; Treluyer JM; Neuraz A;
Cardiovasc Drugs Ther; 2022 Jun; 36(3):483-488. PubMed ID: 33595761
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
10. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
Safizadeh F; Nguyen TNM; Brenner H; Schöttker B
Br J Clin Pharmacol; 2022 Jun; 88(6):2830-2842. PubMed ID: 34935181
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Medication Selection Model Under Clinical Application of Renin-Angiotensin Inhibitor Combined with Calcium Channel Blocker for Hypertension Patients.
Hong D; Shi W; Lu X; Lou Y; Li L
Med Sci Monit; 2020 Apr; 26():e923696. PubMed ID: 32285846
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19.
Pan M; Vasbinder A; Anderson E; Catalan T; Shadid HR; Berlin H; Padalia K; O'Hayer P; Meloche C; Azam TU; Khaleel I; Michaud E; Blakely P; Bitar A; Huang Y; Zhao L; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Reiser J; Eugen-Olsen J; Hayek SS;
J Am Heart Assoc; 2021 Dec; 10(24):e023535. PubMed ID: 34889102
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
Sandhu AT; Kohsaka S; Lin S; Woo CY; Goldstein MK; Heidenreich PA
Am Heart J; 2021 Oct; 240():46-57. PubMed ID: 34126079
[TBL] [Abstract][Full Text] [Related]
16. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
17. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry.
López-Otero D; López-Pais J; Cacho-Antonio CE; Antúnez-Muiños PJ; González-Ferrero T; Pérez-Poza M; Otero-García Ó; Díaz-Fernández B; Bastos-Fernández M; Bouzas-Cruz N; Sanmartín-Pena XC; Varela-Román A; Portela-Romero M; Valdés-Cuadrado L; Pose-Reino A; González-Juanatey JR
Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):175-182. PubMed ID: 32600991
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
[TBL] [Abstract][Full Text] [Related]
19. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
